In a 6‑week postpartum woman who recently started Slynd (desogestrel) and now has significant uterine cramping and bright‑red bleeding, what is the appropriate management?

Management of Postpartum Bleeding on Slynd

First, rule out pregnancy and other pathologic causes, then reassure the patient that irregular bleeding is an expected and common side effect of Slynd that typically improves over time, with NSAIDs as first-line treatment if she wishes to continue the medication.

Initial Evaluation

At 6 weeks postpartum with new-onset cramping and bright red bleeding after starting Slynd, you must systematically exclude serious causes before attributing symptoms to the medication:

Rule Out Pregnancy

• Perform a pregnancy test immediately 1. The FDA label specifically warns about ectopic pregnancy risk with lower abdominal pain on Slynd
• Even if she's been compliant with dosing, pregnancy must be excluded given the cramping and bleeding pattern

Exclude Pathologic Causes

The FDA label explicitly states: "If bleeding persists or occurs after previously regular cycles, evaluate for causes such as pregnancy or malignancy" 1. At 6 weeks postpartum, also consider:

• Retained products of conception (especially with cramping)
• Endometritis (check for fever, foul discharge, uterine tenderness)
• Subinvolution of the placental site
• New uterine pathology (though less likely this early postpartum)

Perform a focused exam checking for cervical motion tenderness, uterine size/tenderness, and assess the bleeding volume.

Understanding Slynd-Related Bleeding

If pathologic causes are excluded, this is most likely medication-related breakthrough bleeding, which is extremely common with Slynd:

• 64.4% of women experience unscheduled bleeding in Cycle 1, decreasing to 40.3% by Cycle 13 1
• The FDA label notes that bleeding irregularities "may resolve over time" 1
• Only 3.5% of women discontinued Slynd due to bleeding disorders in clinical trials 1

This patient is in the highest-risk timeframe for breakthrough bleeding (first 3 months of use), and her symptoms align with expected side effects rather than a contraindication to continued use.

Management Algorithm

If Patient Wants to Continue Slynd:

Provide reassurance that this is expected and will likely improve 2. The 2024 CDC guidelines recommend:

1. First-line treatment: NSAIDs for 5-7 days 2

   • This is the evidence-based intervention for progestin-only pill users with breakthrough bleeding
   • Examples: ibuprofen 400-600mg TID or naproxen 500mg BID

2. Advise her to contact you if bleeding worsens or doesn't improve

3. No need to discontinue unless she desires or develops contraindications

If Patient Wants to Discontinue:

• Remove/discontinue immediately if requested 2
• Offer counseling on alternative contraceptive methods
• Initiate another method if desired
• Consider that combined hormonal contraceptives are now acceptable at 6 weeks postpartum in women without additional VTE risk factors 2, 3

Critical Postpartum Considerations

Thromboembolism Risk

The FDA label specifically warns: "Consider the increased risk of thromboembolism inherent in the postpartum period" 1. However:

• Progestin-only pills like Slynd are safer than combined hormonal contraceptives for VTE risk
• At 6 weeks postpartum, the acute VTE risk period is waning
• Discontinue Slynd immediately if she develops signs of thromboembolism (leg pain, chest pain, severe headache, vision changes) 1

Breastfeeding Status

If she's breastfeeding, Slynd is appropriate and safe 4, 3, 5. Progestin-only contraceptives are recommended immediately postpartum in breastfeeding women.

Common Pitfalls to Avoid

1. Don't dismiss the bleeding without excluding pregnancy and infection - ectopic pregnancy is specifically mentioned as a risk with lower abdominal pain on Slynd 1

2. Don't automatically discontinue the medication - most women's bleeding improves with time, and only 3.5% ultimately discontinue for this reason 1

3. Don't forget to check potassium levels if she has risk factors (kidney disease, certain medications) - though hyperkalemia doesn't cause bleeding, it's a separate monitoring requirement for Slynd 1

4. Don't prescribe combined hormonal contraceptives as an alternative without considering her VTE risk factors - she's still in the window where additional risk stratification is needed (6-12 weeks postpartum) 2, 3